In a patent battle with Pfizer's generic unit Hospira, Astellas is trying to extend the exclusivity of its imaging product Lexiscan. (Christian Richters/View Pictures/Universal Images Group via Getty ...

DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...

Point LomaPoint Loma — A new approach to reducing sickle cell anemia’s painful attacks has entered Phase II clinical trials. The drug, Lexiscan, is already approved for diagnosing heart disease.

Dr. Reddy's is offering regadenoson injection, the generic of Astellas’ Lexiscan injection. Generic Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging ...

It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the ...

WASHINGTON, Nov. 20 (UPI) -- The U.S. Food and Drug Administration warns doctors of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents. The cardiac ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. May 13, ...

Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...

Law360 (May 20, 2022, 7:48 PM EDT) -- Gilead lost its bid to shield its Lexiscan brand of cardiac stress agent from generic competition by Pfizer when the top federal judge in Delaware ruled the new ...

PALO ALTO, Calif., June 24 -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that in conjunction with the commercial launch of Lexiscan(TM) by Astellas Pharma US, Inc., CV Therapeutics has ...

Astellas has won a reprieve in its attempt to stop Pfizer's generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of ...